Next Generation Tissue Biomarkers Market Forecast Highlights Expansion From $3.42 Billion To $5.5 Billion Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Next Generation Tissue Biomarkers Market Size, Value And Growth Trends Through 2030
The market for next-generation tissue biomarkers has experienced notable expansion in recent years. Projected figures indicate an increase from $3.03 billion in 2025 to $3.42 billion in 2026, representing a compound annual growth rate (CAGR) of 12.9%. This historical period growth can be linked to factors such as dependence on conventional histopathology methods, constrained approaches for biomarker discovery, heightened activity in oncology research, wider implementation of companion diagnostic tools, and initial-phase funding allocated to genomic and proteomic investigations.
The market for next-generation tissue biomarkers is anticipated to experience rapid expansion over the coming years. By 2030, its value is projected to reach $5.51 billion, following a compound annual growth rate (CAGR) of 12.6%. This forecasted growth is driven by progress in next-generation sequencing technologies, the incorporation of AI-based tissue analysis, the broadening of spatial biology platforms, increased funding for multi-omics research, and stronger partnerships between pharmaceutical companies and academic institutions. Key developments anticipated during this period include the growing prominence of spatial biology and multi-omics approaches, wider adoption of digital pathology and AI-driven diagnostics, a heightened demand for biomarkers in oncology and companion diagnostics, increased focus on drug discovery and development utilizing tissue biomarkers, and the integration of transcriptomic and metabolomic biomarkers to advance precision medicine.
Download A Free Sample Report For Comprehensive Market Insights:
Next Generation Tissue Biomarkers Market Demand Drivers: What Is Fueling Industry Growth?
The growing preference for tailored medical treatments is expected to fuel the expansion of the next generation tissue biomarkers market in the coming years. Personalized medicine involves customizing healthcare strategies according to an individual’s genetic characteristics, lifestyle choices, and environmental exposures. Its application is on the rise, driven by continuous progress in genomic technologies that enable highly specific and individualized therapeutic approaches. This increasing demand for custom-fit treatments is accelerating the creation of advanced tissue biomarkers, as they offer the detailed and patient-specific data required to align therapies with each person’s unique tissue biology. A notable example comes from the Personalized Medicine Coalition, a US nonprofit, which reported in February 2024 that the FDA authorized 16 new personalized therapies for rare diseases in 2023, a significant jump from 6 approvals in 2022. Among these newly authorized treatments, seven were for various cancers, while three addressed other medical conditions. Consequently, the heightened need for personalized care is propelling forward the next generation tissue biomarkers market.
Next Generation Tissue Biomarkers Market Segment Breakdown: Which Categories Generate The Most Revenue?
The next generation tissue biomarkers market covered in this report is segmented –
1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers
2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies
3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications
4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations
Subsegments:
1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions
2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions
3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation
4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants
5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids
Next Generation Tissue Biomarkers Market Innovation Trends: Which Developments Are Transforming The Industry?
Major players in the next generation tissue biomarkers industry are channeling their efforts into creating advanced tools like genomic-based diagnostic assays and sequencing solutions, all with the aim of boosting the precision, quickness, and tailored nature of cancer detection and therapy. These genomic-based diagnostic assays and sequencing solutions involve instruments and methodologies that analyze genetic data to uncover biomarkers associated with diseases, paving the way for more exact and customized diagnostic and therapeutic strategies. As an example, in August 2024, Illumina Inc., a biotech firm headquartered in the United States, secured FDA clearance for its TruSight Oncology Comprehensive test, along with two companion diagnostic tools, to swiftly link cancer patients with targeted treatments. This assay examines more than 500 genes from a solitary tissue specimen, facilitating accurate treatment determination for a range of solid tumors. It automates biomarker identification and operates around the clock, markedly lowering turnaround periods and enhancing clinical effectiveness, thereby offering a contemporary method for streamlining cancer diagnostics within a regulated environment.
Next Generation Tissue Biomarkers Market Key Players And Strategic Industry Positioning
Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., Biofidelity Ltd.
Access The Complete Next Generation Tissue Biomarkers Market Report:
Next Generation Tissue Biomarkers Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the next generation tissue biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
